Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation |
| |
Authors: | Sonali Rudra Amol K Narang Timothy M Pawlik Hao Wang Elizabeth M Jaffee Lei Zheng Dung T Le David Cosgrove Ralph H Hruban Elliot K Fishman Richard Tuli Daniel A Laheru Christopher L Wolfgang Luis A Diaz Joseph M Herman |
| |
Institution: | 1. Department of Speech Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;2. Department of Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;3. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;4. Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;5. Department of Diagnostic Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;6. Department of Pathology, University of Melbourne, Grattan St, Parkville, Victoria, Australia |
| |
Abstract: | PurposeTo analyze a single-center experience with locally advanced pancreatic cancer (LAPC) patients treated with chemoradiation (CRT) and to evaluate predictive variables of outcome.Methods and MaterialsLAPC patients at our institution between 1997 and 2009 were identified (n = 109). Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier analysis. Cox proportional hazard models were used to evaluate predictive factors for survival. Patterns of failure were characterized, and associations between local progression and distant metastasis were explored.ResultsMedian OS was 12.1 months (2.5-34.7 months) and median PFS was 6.7 months (1.1-34.7 months). Poor prognostic factors for OS include Karnofsky performance status ≤80 (P = .0062), treatment interruption (P = .0474), and locally progressive disease at time of first post-therapy imaging (P = .0078). Karnofsky performance status ≤80 (P = .0128), pretreatment CA19-9 >1000 U/mL (P = .0224), and treatment interruption (P = .0009) were poor prognostic factors for PFS. Both local progression (36%) and distant failure (62%) were common. Local progression was associated with a higher incidence of metastasis (P < .0001) and decreased time to metastasis (P < .0001).ConclusionsLAPC patients who suffer local progression following definitive CRT may experience inferior OS and increased risk of metastasis, warranting efforts to improve control of local disease. However, patients with poor pretreatment performance status, elevated CA19-9 levels, and treatment interruptions may experience poor outcomes despite aggressive management with CRT, and may optimally be treated with induction chemotherapy or supportive care. Novel therapies aimed at controlling both local and systemic progression are needed for patients with LAPC. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|